UV exposure boosts transcutaneous immunization and improves tumor immunity: Cytotoxic T-cell priming through the skin

Journal of Investigative Dermatology

Volumn 131, Issue 1, 2011, Pages 211-219

  Stein, Pamela ^a   Rechtsteiner, Gerd ^a,c   Warger, Tobias ^a,d   Bopp, Tobias ^a   Fuhr, Thorsten ^a   Prüfer, Steve ^a   Probst, Hans Christian ^a   Stassen, Michael ^a   Langguth, Peter ^b   Schild, Hansjörg ^a   Radsak, Markus P ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c FRESENIUS MEDICAL CARE   (Germany)

^d Schering Plough ^*  (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P 15095; IMIQUIMOD; LANGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; TUMOR; TUMOR GROWTH; TUMOR IMMUNITY; ULTRAVIOLET RADIATION;

EID: 78650277948     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.254     Document Type: Article

References (33)

1. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-52
2. Bennett CL, Van Rijn E, Jung S et al. (2005) Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitiv-ity. J Cell Biol 169:569-76
3. Biggs L, Yu C, Fedoric B et al. (2010) Evidence that vitamin D3 promotes mast cell-dependent reduction of chronic UVB-induced skin pathology in mice. J Exp Med 207:455-63
4. Bursch LS, Wang L, Igyarto B et al. (2007) Identification of a novel population of Langerin+ dendritic cells. J Exp Med 204:3147-56
5. Chang SY, Cha HR, Igarashi O et al. (2008) Cutting edge: Langerin+ dendritic cells in the mesenteric lymph node set the stage for skin and gut immune system cross-talk. J Immunol 180:4361-5
6. Cooper KD, Baron ED, Matsui MS (2003) Implications of UV-induced inflammation and immunomodulation. Cutis 72:11-5
7. Fisher MS, Kripke ML (1982) Suppressor T lymphocytes control the development of primary skin cancers in ultraviolet-irradiated mice. Science 216:1133-4
8. + T regulatory cells and is dependent on host-derived IL-10. J Immunol 176:2635-44
9. Ginhoux F, Collin MP, Bogunovic M et al. (2007) Blood-derived dermal Langerin+ dendritic cells survey the skin in the steady state. J Exp Med 204:3133-46
10. Halliday GM, Lyons JG (2008) Inflammatory doses of UV may not be necessary for skin carcinogenesis. Photochem Photobiol 84:272-83
11. Heath WR, Carbone FR (2009) Dendritic cell subsets in primary and secondary T cell responses at body surfaces. Nat Immunol 10:1237-44
12. Heib V, Becker M, Warger T et al. (2007) Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice. Blood 110:946-53
13. Hemmi H, Kaisho T, Takeuchi O et al. (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196-200
14. Itoh T, Celis E (2005) Transcutaneous immunization with cytotoxic T-cell peptide epitopes provides effective antitumor immunity in mice. J Immunother 28:430-7
15. Jung S, Unutmaz D, Wong P et al. (2002) In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17:211-20
16. Kissenpfennig A, Henri S, Dubois B et al. (2005) Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22:643-54
17. Maeda A, Beissert S, Schwarz T et al. (2008) Phenotypic and functional characterization of ultraviolet radiation-induced regulatory T cells. J Immunol 180:3065-71
18. Merad M, Manz MG, Karsunky H et al. (2002) Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 3:1135-41
19. Navi D, Huntley A (2004) Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J 10:4
20. Palamara F, Meindl S, Holcmann M et al. (2004) Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 173:3051-61
21. Porgador A, Yewdell JW, Deng Y et al. (1997) Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6:715-26
22. Poulin LF, Henri S, de Bovis B et al. (2007) The dermis contains langerin+ dendritic cells that develop and function independently of epidermal Langerhans cells. J Exp Med 204:3119-31
23. Rana S, Byrne SN, MacDonald LJ et al. (2008) Ultraviolet B suppresses immunity by inhibiting effector and memory T cells. Am J Pathol 172:993-1004
24. Rechtsteiner G, Warger T, Osterloh P et al. (2005) Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 174:2476-80
25. Romani N, Koide S, Crowley M et al. (1989) Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 169:1169-78
26. Schwarz A, Maeda A, Wild MK et al. (2004) Ultraviolet radiation-induced regulatory T cells not only inhibit the induction but can suppress the effector phase of contact hypersensitivity. J Immunol 172:1036-43
27. + effector and memory T cell generation. Nat Immunol 4:835-42
28. Stoitzner P, Green LK, Jung JY et al. (2008) Tumor immunotherapy by epicuta-neous immunization requires Langerhans cells. J Immunol 180:1991-8
29. Thatcher TH, Luzina I, Fishelevich R et al. (2006) Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance. J Invest Dermatol 126:821-31
30. Thomsen LL, Topley P, Daly MG et al. (2004) Imiquimod and resiquimod in a mouse model: adjuvants for DNA vaccination by particle-mediated immunotherapeutic delivery. Vaccine 22:1799-809
31. Walterscheid JP, Nghiem DX, Kazimi N et al. (2006) cis-Urocanic acid, a sunlight-induced immunosuppressive factor, activates immune suppression via the 5-HT2A receptor. Proc Natl Acad Sci USA 103:17420-5
32. Warger T, Hilf N, Rechtsteiner G et al. (2006) Interaction of TLR2 and TLR4 ligands with the N-terminal domain of Gp96 amplifies innate and adaptive immune responses. J Biol Chem 281:22545-53
33. Warger T, Rechtsteiner G, Schmid B et al. (2007) Transcutaneous immunization with imiquimod is amplified by CD40 ligation and results in sustained cytotoxic T-lymphocyte activation and tumor protection. Clin Rev Allergy Immunol 32:57-66